Invivosciences was invited to attend Rare Diseases Summit November 15-17, 2017
Dr. Wakatsuki was invited to present at Kirishima Symposium in Tokyo kirishima_4th_poster_jp
Contact details: Ayla Annac, CEO/President of lnvivoSciences Inc. +1-608-628-8035. aannac@ invivosciences.com Cardiovascular safety liabilities caused 52.3 % of 44 marketed data from 1980 to 2011, and cardiovascular disease remains the leading cause of death globally, yet only 8.7% of cardiovascular drugs successfully pass clinical trials. These statistics demonstrate the need to address a patient’s specific genetic make-up and…
Read more
InvivoSciences’ CEO/Co-Founder, Ayla Annac, has been invited to speak at the BME Tong Distinguished Entrepreneur Lecture Series Spring 2016. She will be presenting on Friday, March 11 2016 at the Marquee Theater in Union South from 12-1 pm. This event is open to the public. The event is sponsored by the Department of Biomedical Engineering and Mr.…
Read more
InvivoSciences wishes all a happy and prosperous new year!
InvivoSciences was one of the sponsors supporting the Lussier Community Education Center’s Halloween-themed science night in Madison, WI on October 30, 2015.
InvivoSciences’ CEO/Co-Founder, Ayla Annac, has been invited to speak at the 2016 Biotech and The Law Global Conference & Expo. Her presentation, “Therapeutic Advancement: Developing Drug Discovery Platforms,” will discuss InvivoSciences’ continuing role in the development of precision medicine, particularly the impact of our 3D human tissue model systems on toxicity studies. She will be presenting on…
Read more
InvivoSciences was featured in the October 2015 issue of MedTech Dealmakers. The article is titled “Predicting Cardiotoxicity with Engineereed 3D Human Cardiac Tissue Models.” InvivoSciences harnesses human induced pluripotent stem cells to generate patient-specific disease models for drug and diagnostics development.
Dr. Wakatsuki was interviewed and quoted in the September 2015 GEN article titled, “Feng Shui Basics for 3D Cell Culture.” The author writes about how our engineered heart tissues (EHT) “(bring) practical applications to personalized medicine.”
Recent Comments